Abstract 2421
Background
Co-inhibiting angiogenesis and PD-1/PD-L1 is a promising regimen for several solid tumours; however, its role in bile tract carcinoma (BTC) remains unclear. We sought to investigate the antitumour efficacy and toxicity of lenvatinib (an oral anti-angiogenesis drug) plus PD-1 blockade in patients with advanced BTC.
Methods
A retrospective cohort study involved patients with advanced BTC who have treated with lenvatinib plus PD-1 blockade. The PD-1 inhibitors only included pembrolizumab and nivolumab. The primary outcomes of this study were the objective response rate (ORR) and progression-free survival (PFS). Biomarkers, including PD-L1 expression, tumour mutational burden (TMB) and genetic alterations, were analysed.
Results
In total, 56 patients (29 with lenvatinib plus nivolumab, 27 with lenvatinib plus pembrolizumab) were enrolled. The ORR was 30.4%, the disease control rate was 85.7%, and the clinical benefit rate was 50%. The median PFS was 5.0 months (95% CI: 4.0-6.0), and the median overall survival was 11.0 months (95% CI: 6.6-15.4). For tolerability, 96.4% of the patients had adverse events (AEs), but only 19.6% of the patients experienced grade-3 AEs without grade-4/5 AEs occurring. Fatigue, hypertension and hypothyroidism were the most common AEs. Moreover, PD-L1 positive expression had higher ORR and longer PFS, while TMB was not correlated with the response and survival outcomes. Further analysis of efficacy-related factors demonstrated that patients with resected BTC could obtain longer OS.
Conclusions
Lenvatinib plus PD-1 inhibitor presents an effective and safe strategy in patients with advanced BTC, especially those with PD-L1 positive expression and prior surgical resection.
Clinical trial identification
NCT03892577.
Editorial acknowledgement
Milind Javle.
Legal entity responsible for the study
The protocol of this study was compliant with the principles of the Declaration of Helsinki and was also approved by the institutional review board and ethics committee of PUMCH.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract